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Abstract
There is clear evidence for intraluteal production of prostaglandins (PGs) in numerous species and
under a variety of experimental conditions. In general, secretion of PGs appears to be elevated in
the early corpus luteum (CL) and during the period of luteolysis. Regulation of intraluteal PG
production is regulated by a variety of factors. An autoamplification pathway in which PGF-2alpha
stimulates intraluteal production of PGF-2alpha has been identified in a number of species. The
mechanisms underlying this autoamplification pathway appear to differ by species with expression
of Cyclooxygenase-2 (Cox-2) and activity of phospholipase A2 acting as important physiological
control points. In addition, a number of other responses that are induced by PGF-2alpha (decreased
luteal progesterone, increased endothelin-1, increased cytokines) also have been found to increase
intraluteal PGF-2alpha production. Thus, regulation of intraluteal PG production may serve to
initiate or amplify physiological signals to the CL and may be important in specific aspects of luteal
physiology particularly during luteal regression.
Introduction
Although progesterone is the major luteal hormone, the
CL also produces a number of other substances including
prostaglandins (PGs) and oxytocin. The PGs are of partic-
ular interest because of their potential autocrine/paracrine
actions within the CL. The involvement of PGF2α in regres-
sion of the CL in many species makes it likely that there is
a role for intraluteal PGF2α production in luteal regres-
sion. In addition, functional roles for PGs in the early CL
have also been postulated [1,2]. In this review the general
pathways in PG production will be reviewed (Section I)
before discussion of the evidence for and the timing of
intraluteal PG production in various species (Section II).
Although many factors can regulate intraluteal PG pro-
duction, amplification pathways within the CL that are
induced by PGF2α (Section III) or other factors (Section
IV) will be emphasized in this review. Some speculations
on the physiological role of intraluteal PG production are
also provided (Section V). Other excellent reviews have
been previously published on regulation of intraluteal PG
production [1,2] that contain material not discussed in
this review.
General Pathways for Production of 
Prostaglandins
Prostaglandins are derivatives of membrane phospholip-
ids that regulate diverse physiological processes such as
pregnancy, ovulation, luteolysis, inflammation, gastric
secretion, and blood flow. The substrates for PG synthesis
are arachidonylated phospholipids, such as plasmenyl-
choline, phosphatidylcholine, and alkylacyl glycerophos-
phorylcholine. Prostaglandin biosynthesis begins with
the liberation of arachidonic acid from these membrane
phospholipids. This step is primarily catalyzed by the hor-
mone-responsive enzyme cytosolic phospholipase A2
(cPLA2) [3]. The cPLA2 is one member of a larger family of
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enzymes organized into 11 groups (I-XI) that also include
various secreted forms of PLA2 [4]. An increase in free
intracellular calcium can cause activation of cPLA2 by
binding to an amino-terminal domain causing transloca-
tion to cellular membranes, particularly to the nuclear
envelope and endoplasmic reticulum, where it can hydro-
lyze arachidonic acid from membrane phospholipids (see
review by Gijon and Leslie [5]). However, one study did
not detect translocation of cPLA2, but found that active or
inactive cPLA2 was randomly distributed in the cytoplasm
[6]. Phosphorylation by MAP kinases of Ser 505 [7] can
also contribute to full activation of cPLA2. In some cell
types, activation of PKC and/or inhibition of certain phos-
phatases with okadaic acid also contribute to cPLA2 activa-
tion [5]. Recent findings indicate that there is sustained
cPLA2 activity during luteolysis in the pseudopregnant rat
[8].
Free arachidonic acid is converted to PGH2 by the enzyme
cyclooxygenase (Cox). This is generally considered the
rate-limiting step in PG production and commits arachi-
donic acid to the PG synthesis pathway. There are two
enzymatic steps in the conversion of arachidonic acid to
PGH2. First, a cyclooxygenase step that catalyzes the con-
version of arachidonic acid to PGG2 and a second peroxi-
dase step that reduces PGG2  to PGH2. At least two
isoforms of Cox exist, Cox-1 and Cox-2 that catalyze con-
version of arachidonic acid to PGH2 through a similar cat-
alytic site and mechanism. A third Cox isoform, Cox-3,
was postulated [9] and has been recently isolated and
characterized [10]. This enzyme is derived from the Cox-1
gene but with retention of intron 1 in the mRNA. The
physiological function of this third isoform or other Cox
isoforms has not yet been determined, but Cox-3 may be
the elusive target for acetaminophen action [10]. Cox-1 is
characterized by constitutive expression in many tissues
and may regulate various homeostatic functions such as
arterial blood pressure [11] and gastric epithelium func-
tion [12]. Cox-2 is inducible in many tissues and has been
found to regulate PG production during many acute
responses such as inflammation [13]. Many non-steroidal
anti-inflammatory drugs such as aspirin and indometh-
acin inhibit both Cox-1 and Cox-2; there are now Cox-2
specific inhibitors available commercially and for
research purposes. Regulation of Cox-2 expression has
been clearly demonstrated in the CL, as discussed below.
There is no clear evidence that we are aware of that arachi-
donic acid requires specific transport proteins to reach the
Cox enzymes; however, there appears to be utilization of
different arachidonic acid pools by Cox-1 and Cox-2
within the same cell. Antisense Cox-2 RNA treatment of
murine macrophages blocks endotoxin-induced PGE2
production, but not arachidonic acid release. The consti-
tutively present Cox-1 enzyme in these cells was unable to
use this pool of endotoxin-stimulated arachidonic acid
[14]. Surprisingly, addition of exogenous arachidonic acid
to the media could be utilized by Cox-1, but not by Cox-
2. In mouse mast cells, cytokine treatment (IL-10 + IL-1β
+ Kit ligand) induces Cox-2 and PGD2production, while
IgE plus hapten-specific antigen induces Cox-1-mediated
PGD2 production that is not affected by the presence of
Cox-2 [15]. These results in macrophages and mast cells
indicate that Cox-1 and Cox-2 utilize different pools of
arachidonic acid. The subcellular localization of Cox-1
and Cox-2 differ and this may be important for the differ-
ential use of substrate by these enzymes. Intense Cox-2
immunostaining is observed on the nuclear membrane,
while Cox-1 immunostaining is equally localized to the
ER and nuclear membrane [16]. Using a histoflouresense
method for determining Cox activity, Morita et al. [16]
found Cox-1 activity associated mainly with the ER, while
Cox-2 activity was mostly in the nucleus. Intriguingly, as
mentioned above, activated cPLA2 also localizes to perinu-
clear membranes. Thus, activated cPLA2 and Cox-2 may be
in close subcellular proximity and this may explain why
cPLA2-released arachidonic acid is utilized by Cox-2 while
exogenously-added arachidonic acid is utilized by Cox-1
(reviewed in [5]). Subcellular distributions and differen-
tial utilization of arachidonic acid has not yet been exper-
imentally evaluated in the CL.
After conversion of arachidonic acid to PGH2 there can be
production of a wide variety of PGs according to the par-
ticular PG synthase enzymes that are present. The PGF-
synthase enzyme has been cloned and is a member of the
aldo-keto reductase family of enzymes that includes 20α-
hydroxysteroid dehydrogenase [17]. PGF-synthase mRNA
has been identified in the CL but PGF2α treatment did not
alter steady-state PGF-synthase mRNA concentrations
[18]. Many cells, including luteal cells, have been found to
produce multiple PGs that may have differential actions
[19]. In luteal cells from day 17 pseudopregnant pigs,
there is induction of luteal production of both PGF2α and
PGE2 by treatment with PGF2α [20]. This is surprising
because PGF2α is considered to be luteolytic while PGE2 is
considered to be luteotropic. Thus, although differential
expression of PG synthase enzymes seems like a potential
mechanism to direct production of specific PGs, we have
not yet found evidence of this differential regulation in
the luteal cell literature.
Intraluteal metabolism of PGF2α could also be a physio-
logically regulated event. It has been known for many
years that there is an enzymatic activity termed PGE2-9-
ketoreductase that can convert PGF2α to PGE2 or alterna-
tively PGE2 to PGF2α [21]. Similar to PGF-synthase, this
enzyme was found to be part of the aldo-keto reductase
family of enzymes [22]. Surprisingly, a pure preparation
of the 20α-hydroxysteroid dehydrogenase enzyme wasReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/91
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found to also contain PGE2-9-ketoreductase activity [22].
Similarly, the sequences of the mRNA for these 2 enzymes
are identical [23] suggesting that the enzyme that inacti-
vates progesterone may also inter-convert PGs within the
CL. Nevertheless, a functional role for PG conversion
activity by this enzyme in the CL has not been deter-
mined. PGF2α can also be metabolized to the inactive PG,
13,14-Dihydro-15-Keto-PGF2α  (PGFM) by the enzyme
15-hydroxyprostaglandin dehydrogenase (PGDH) [24].
Local metabolism of PGs has been reported in many tis-
sues including the CL [25]. We found that PGDH mRNA
was abundant in the pig CL [20]. In the sheep CL, PGDH
activity is greatest in the early CL and during maternal rec-
ognition of pregnancy, both times when the CL is rela-
tively resistant to PGF2α action [25]. This suggests that
PGDH expression may have a luteoprotective role in the
CL by inactivating any PGF2α that is produced; however,
this hypothesis will require further experimental
evaluation.
Prostaglandins have both hydrophobic and hydrophilic
domains that should make it difficult for these com-
pounds to traverse cellular membranes. Indeed, cellular
transporters of PGs have been identified. These PG trans-
porters contain 12 transmembrane domains and are part
of the organic anion transport class of transmembrane
proteins [26]. Expression of these transporters in Xenopus
oocytes or HeLa cells allows entry of PGs into these cells
[26]. Cell that synthesize PGs (as determined by Cox
expression) also have substantial expression of the PG
transporter [27] and this may be important for release of
the synthesized PGs. Similarly, it seems likely that expres-
sion of PG transporters may be required to allow secretion
of PGs from luteal cells; although this idea has never been
tested.
Intraluteal actions of PGs are likely to be mediated
through the plasma membrane PG receptors that are
pharmacologically designated by their major PG ligand.
For example, the receptors that bind PGF2α with high
affinity have been designated FP receptors; whereas, the
receptors that bind PGEs with high affinity are designated
as EP1, EP2, EP3, and EP4. The FP receptor mRNA is
induced in bovine granulosa cells within 1 d after the LH
surge and is expressed at more than 100-fold greater con-
centration in the CL than in any other tissue [28]. Binding
to the plasma membrane FP receptor probably requires an
extracellular location for PGF2α to cause activation. There
also appears to be expression of EP3 receptor in the CL;
however, it is present at much lower concentrations than
luteal FP receptor [28]. Conversely, intracellular PGs
could potentially interact with specific peroxisome prolif-
erator activated receptors (PPARs). The PPARs act as tran-
scriptional factors and PPARγ has been found to be
activated by PGJ2, a metabolite of PGD2 [29]. It seems
likely that regulation of the transport of PGs through the
plasma membrane (extracellular vs. intracellular) could
be a mechanism for regulation of functional effects by
luteal cell-derived PGs. This manuscript will primarily dis-
cuss the luteal production of PGs; however, a complete
understanding of luteal PG action must also consider the
diversity of distinct PG receptors linked to varying intrac-
ellular effector systems within the CL.
Changes in Intraluteal PG Production During 
the Luteal Phase
As mentioned above, the corpora lutea of various species
have the capacity to synthesize PGs (rats [19], rabbits [30],
pigs [31-34], sheep [18,35], cows [36,37], horses [38],
rhesus monkeys [39], cynomolgus monkeys [40], women
[41]). Investigators have assessed the pattern of change in
luteal PG production throughout the luteal phase in a
number of different species. The objective of these experi-
ments was frequently to determine if changes in luteo-
tropic or luteolytic PGs coincided with developmental or
regressive changes in luteal function. Often this was done
by surgically removing the corpora lutea at three to four
different stages of the cycle or pseudopregnancy. These
stages represented luteal developmental (early luteal
phase), maximal function (mid-luteal phase), and luteal
regression (late luteal phase). Dispersed cells or tissue
samples were incubated to assess their capacity to produce
the various prostaglandins. Luteotropic PGs examined
were PGE2 and PGI2 (as reflected by its major metabolite
6-keto-PGF1α). The luteolytic PG examined was PGF2α.
Below we will discuss some experiments of this nature in
various species.
Rats
Prior to examining luteal production of PGs in rats, stud-
ies were designed to examine how luteal concentrations of
PGs varied throughout pseudopregnancy. Luteal concen-
trations of PGF2α increased as the luteal phase progressed
from day 7 to 13 of pseudopregnancy in rats [42]. Luteal
concentrations of PGE were greatest on day 11 and
decreased by day 13. Luteal production of PGF2α and
PGE2 increased from day 7 to 10 and declined to day 13 of
pseudopregnancy [19]. These increases in PG production
coincided with the onset of decreased luteal progesterone
production as the CL transitioned from day 7 to 10. Luteal
production of 6-keto-PGF1α did not change over time.
Pigs
Porcine luteal tissue was collected from the slaughter-
house and staged on the basis of morphological and his-
tological criteria. Corpora lutea were assigned to the
following groups: early luteal (day 3–6), mid-luteal (day
7–14), and late-luteal (including corpora albicantes, day
15–19) [33]. Production of PGF2α and PGE2 decreased
from the early to the mid-luteal phase and rebounded inReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/91
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the late luteal phase. The rise in PGF production from the
mid to late luteal phase supports an earlier study from the
same authors [34]. Using pigs whose stage of the estrous
cycle was carefully monitored, Guthrie and Rexroad stud-
ied changes in luteal prostaglandin production in CL col-
lected on day 8, 12, 14, 16, and 18. They also observed an
increase in PGF2α production as the corpus luteum transi-
tioned from mid to late luteal phase [31].
Cows
Early bovine CL produced the highest levels of PGI2 (as
reflected by its major metabolite 6-keto-PGF1α) and PGF2α
compared to mid- and late cycle [36]. Similar results were
observed by Rodgers et al. [43]. These patterns of change
in luteal production over time were reflected in the initial
prostaglandin content. The ratio of the initial content of
PGF2α:6-keto-PGF1α  increased as the cycle progressed
[36]. Koybayashi et al. [44] used an intraluteal microdial-
ysis system to study production of luteal prostaglandins in
vivo during days 3–6 of the estrous cycle. They found that
luteal secretion of PGF2α and PGE2 was elevated on day 3
and was relatively diminished on days 4–6. Consistent
with these results on PG secretion, they also found that
luteal concentrations of Cox-2 mRNA were greater in the
early than in the mid to late luteal phase. In an experiment
by Grazul et al. [45], patterns of luteal production of
PGF2α did not vary significantly by stage of cycle. DelVec-
chio et al. [46-48] compared luteal production of prostag-
landins collected at two stages of the estrous cycle. They
found that luteal cells derived from late bovine CL pro-
duced more PGE2 and PGF2α than those derived from
mid-cycle CL.
Horses
Corpora lutea were collected from mares on days 4–5, 8–
9, and 12–13 [38]. Production of PGF, PGE2, and 6-keto-
PGF1α was highest in corpora lutea collected in the early
luteal phase. PGE2 production increased from CL col-
lected on days 8–9 to days 12–13, but production of the
other prostaglandins did not change over this interval.
The ratio of PGF:PGE2 increased from days 4–5 to days 8–
9, and remained higher than early in the luteal phase on
days 12–13.
Non-human old world primates
In the rhesus monkey [49], luteal production of PGE2 and
6-keto-PGF1α, was highest in the early luteal phase,
decreased in mid-luteal phase, and remained suppressed
in late luteal phase. The notion of a luteotropic role for
PGE2 and PGI2 in primate CL was supported by significant
positive correlations between luteal production of P and
that of PGE2 and 6-keto-PGF1α (the stable metabolite of
PGI2). Concentrations of PGF2α  decreased from early
luteal phase to mid-luteal phase, but in contrast to the
luteotropic PGs, rebounded in late luteal phase to levels
observed in early luteal phase. No differences were
observed in the ratio of PGE2/PGF2α during the luteal
phase, but there was a tendency for an increase in the ratio
of PGF2α :6-keto-PGF1α from early luteal phase to mid-
luteal phase, similar to the results from studies in cattle
[36].
In the cynomolgus monkey, luteal production of PGF2α
was highest in the early luteal phase, and there was no
apparent rebound in the late luteal phase as was observed
in the rhesus monkey [40]. Luteal production of PGE2 was
high in the early luteal phase, decreased in the mid-luteal
phase, and rebounded in late luteal phase to levels
observed in early luteal phase.
Humans
Prior to studying luteal PG production, the content of PGs
in the human CL was considered. In two experiments
[50,51] there was a significant increase in luteal PGF2α
concentration as the CL progressed from the mid to late
luteal phase. Swanston et al. [52] also observed an
increase in luteal content of PGF2α, but this increase
occurred as late CL became corpora albicantes. Patward-
han and Lanthier [41] observed an increase in PGF con-
tent as the CL progressed from early to mid-luteal phase,
and the high level was maintained during the late luteal
phase.
Recently, PG production by human CL of different stages
was assessed [53]. In this study, only two stages were con-
sidered, mid-luteal phase (days 5–9 after ovulation) and
late luteal phase (days 10–14 after ovulation). Luteal pro-
duction of PGF2α, PGE2, and 6-keto-PGF1α were signifi-
cantly higher in the mid vs. late luteal phase.
To evaluate relative changes in PG synthetic enzymes over
time, human CL were studied using immunocytochemis-
try [54]. Cyclooxygenase and PGF2α  synthase were
reported to qualitatively increase from early to mid-luteal
phase and to further intensify by late luteal phase. Pros-
taglandin I2 synthase appeared to be most prevalent in
mid-luteal phase CL when compared to the other two
stages examined. These data are consistent with the
notion that luteal production of luteolytic PG increases as
the luteal phase progresses in the woman. The data sup-
port the studies mentioned above with respect to luteal
content of PGF2α [41,50-52], but they are not consistent
with the PG production data of Friden et al. [53].
In assessing these types of studies, it can be seen that dif-
ferences exist in the patterns of luteal PG production
across species and experiments. However, with some
exceptions, there are similarities that can be noted. First of
all, luteal production of luteolytic and luteotropic PGs is
often high in the early luteal phase. Many have suggestedReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/91
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that the luteotropic PGs may play a role in luteal develop-
ment, and it is well known that young corpora lutea are
not sensitive to the luteolytic effects of PGF2α. Addition-
ally, in many studies/species there is either an increase in
production of PGF2α as the CL ages from mid- to late
luteal phase, or there is an increase in the ratio of PGF2α
:PGE2 or PGF2α :6-keto-PGF1α. As such, the balance of lute-
olysin to luteotropin often favors the luteolysin in the late
luteal phase. Thus, a combination of changes in luteal
production of luteotropic and luteolytic PGs and changes
in the responsiveness of luteal tissue to these PGs may
play a role in controlling luteal function in various
species.
Regulation of Intraluteal PG by PGF2α
One of the most intriguing aspects of luteal PGF2α produc-
tion is that there appears to be an autoamplification loop
such that treatment of luteal cells with PGF2α induces pro-
duction of PGF2α by luteal cells. In initial reports of this
phenomenon, researchers treated sheep [35] or pigs [55]
with cloprostenol (PGF2α analog) in vivo, removed the cor-
pora lutea, and then incubated luteal slices in vitro. In
these studies treatment in vivo with a PGF2α analog dra-
matically increased the in vitro production of PGF2α. Sim-
ilarly, treatment of large luteal cells in vitro with PGF2α or
activation of PGF2α second messenger pathways (free cal-
cium, activation of PKC) can increase PGF2α production in
vitro [18,20]. As shown in Figure 1, this increase in PGF2α
production only occurs in CL with luteolytic capacity
(from pigs on day 17 of pseudopregnancy) and not in CL
without luteolytic capacity (day 9 of the estrous cycle)
[20]. Thus, there is clear evidence for an intraluteal posi-
tive feedback pathway for PGF2α  production and this
pathway appears to be associated only with CL that
undergo regression after a single treatment with PGF2α.
There are probably multiple intracellular mechanisms
involved with PGF2α-induced production of intraluteal
PGF2α. There is evidence that PLA2 activity is increased
during luteolysis [56]. Treatment with PGF2α dramatically
increases free intracellular calcium in large luteal cells [57]
and free calcium will bind to cPLA2 causing translocation
to the nuclear membranes. In addition, PGF2α treatment
activates MAP kinases [58] and activates PKC [59], both
intracellular effectors that can contribute to activation of
cPLA2. There was no detectable increase in luteal cPLA2
mRNA after in vivo treatment with PGF2α [60], suggesting
that luteal changes in cPLA2 were probably mediated by
protein activation rather than transcriptional regulation.
Thus, treatment of CL with PGF2α  is likely to cause
Secretion of (A) progesterone and (B) PGF2α from tissues from gilts on day 9 of the estrous cycle or day 17 of pseudopreg- nancy treated in vivo with a PGF2α analog (Cloprostenol) 10 hours prior to ovary removal Figure 1
Secretion of (A) progesterone and (B) PGF2α from tissues from gilts on day 9 of the estrous cycle or day 17 of pseudopreg-
nancy treated in vivo with a PGF2α analog (Cloprostenol) 10 hours prior to ovary removal. Progesterone and PGF2α were 
measured in media following 2 hour incubation of collected porcine luteal tissue. A, B – statistically different (P < 0.05) within 
day (from [20]).
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translocation and activation of cPLA2 through a number
of key intracellular pathways allowing liberation of free
arachidonic acid from membrane phospholipids. Treat-
ment in vivo with PGF2α also dramatically increases expres-
sion of Cox-2 mRNA and protein [18,20,61]. In vitro
treatment of large luteal cells with PGF2α or activators of
intracellular effector systems that are activated by PGF2α
also dramatically increased Cox-2 mRNA, protein, and
PGF2α production [18,20]. Thus, PGF2α will activate both
of the key rate-limiting steps in PGF2α production by acti-
vating the cPLA2 protein and by inducing Cox-2 activity.
The molecular mechanisms involved in PGF2α induction
of Cox-2 have been analyzed. There was about a 40-fold
induction of reporter gene expression following treatment
of transfected large luteal cells with PGF2α  [62]. This
induction could be inhibited by a specific inhibitor of
PKC, myristolated pseudosubstrate for PKCα and β.
Inhibitors of calcium calmodulin kinase and the MAP
kinase pathways had no effect on PGF2α induction of Cox-
2. We have found that there are three key DNA response
elements in the 5' flanking DNA region that act synergisti-
cally to regulate induction of Cox-2 by PGF2α in ovine
large luteal cells [62]. The most critical element is an E-
box region that is about 50 bp upstream of the transcrip-
tion initiation site. Thus, PGF2α, acting through PKC and
an E-box DNA element, specifically increases Cox-2 gene
transcription.
The mechanisms underlying the stage-specific regulation
of this autoamplification pathway remain unresolved in
spite of recent studies using a variety of luteal models. In
the bovine CL, PGF2α induces expression of Cox-2 mRNA
only in CL with luteolytic capacity (day 11 of estrous
cycle). In the bovine CL without luteolytic capacity (day
4), treatment with PGF2α induces a number of cellular
responses, indicating that the PGF2α  does activate FP
receptors in the early CL, but there is no induction of Cox-
2 mRNA [61,63]. In non-luteinized granulosa cells, activa-
tion of protein kinase (PK) A by cAMP was a potent stim-
ulator of Cox-2 gene expression; whereas, PGF2α had no
effect on Cox-2 expression. However, after 7 days of lutei-
nization during culture, PGF2α became a potent stimula-
tor of Cox-2 expression, similar to the timing observed in
vivo  [64]. In ovine granulosa cells, Cox-2 mRNA and
PGF2α secretion were also induced by activation of the
PKA but not the PKC pathway [62]. In contrast in ovine
large luteal cells, Cox-2 mRNA and PGF2α production
were primarily stimulated by PKC and not PKA. Wu and
Wiltbank used bovine granulosa cells to evaluate the
changes in expression of the Cox-2 promoter linked to a
luciferase reporter during luteinization and acquisition of
luteolytic capacity [65]. In non-luteinized granulosa cells,
activation of PKA but not PKC dramatically increased
Cox-2 promoter-driven expression. However, after 8 days
of luteinization the promoter became responsive to PKC
and PGF2α but not to PKA activation. Intriguingly, the
induction of the Cox-2 promoter by either PKA (non-
luteinized granulosa cells) or PKC (luteinized granulosa
cells) was mediated by the E-box element mentioned
above. Tsai et al., also found that human granulosa-lutein
cells, only display this PGF2α autoamplification pathway
after 8 days of luteinization [66]. In early granulosa-lutein
cells (day 2 of culture) there is no increase in Cox-2 in
response to PGF2α treatment. However after 8 days of
luteinization, PGF2α dramatically induced Cox-2 mRNA
and inhibited progesterone production, indicating the
acquisition of luteolytic capacity develops over time in
culture.
In contrast to the studies cited above using bovine, ovine,
and human luteal or granulosa-lutein cells, studies with
the pig CL have not found an association between luteal
Cox-2 expression, luteal PGF2α production, and luteolytic
capacity [20]. In vivo treatment with PGF2α  induced
expression of Cox-2 mRNA and protein in either CL with-
out luteolytic capacity (day 9) or with luteolytic capacity
(day 17). However, there was no increase in luteal PGF2α
production in day 9 CL (Figure 1) in spite of the dramatic
induction of Cox-2 mRNA. We were unable to determine
the rate-limiting step that prevented induction by PGF2α
of intraluteal PGF2α production in the early pig CL [20].
The physiological significance of this autoamplification
pathway has not yet been clearly defined but it would
allow small amounts of PGF2α from the uterus to induce a
dramatic increase in intraluteal PGF2α production. Intral-
uteal PGF2α production may be crucial for complete lute-
olysis. In an elegant series of recent experiments, Griffeth
et al. [67], found that intraluteal treatment with the PG
synthesis inhibitor, indomethacin, prevented the decrease
in luteal weight that is normally associated with luteal
regression; although, the decrease in luteal progesterone
production was not affected. Intriguingly, they also
reported that in hysterectomized ewes, doses of PGF2α (1
mg and 3 mg) that caused luteal regression also induced
peaks of PGFM at 12–36 hours after PGF2α treatment.
These peaks of PGFM were not of uterine origin and may
have originated from the CL.
Other Regulators of Intraluteal PG Production
It appears that secretion of PGF2α and progesterone are
interrelated. Treatment of CL that have luteolytic capacity
with exogenous PGF2α inhibits progesterone production.
Conversely, treatment of bovine luteal cells with proges-
terone decreased PGF2α production in a dose-dependent
fashion [68]. However, progesterone may affect intral-
uteal PG production differently in CL with or without
luteolytic capacity. Okuda and Skarzynski [1] reported
that blockade of the progesterone receptor with a highlyReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/91
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selective progesterone antagonist, onapristone, inhibited
PGF2α production by bovine luteal cells from the early CL
(Days 4–5); whereas, onapristone treatment increased
PGF2α production by bovine luteal cells from mid-cycle
CL (Days 8–12). Thus, the effect of progesterone in regu-
lating intraluteal PG production may shift from stimula-
tory to inhibitory during luteal development.
Cytokines are also potent stimulators of luteal PGF2α pro-
duction. Interleukin-1β and tumor necrosis factor-α dra-
matically stimulated PGF2α  production by cultured
bovine luteal cells [37,69,70]. The acute stimulation of
PGF2α production has been postulated to occur through
activation of cPLA2 [70-72]. The chronic effects (72 h) of
interleukin-1β may be mediated by upregulation of Cox
[70]. In human luteinized granulosa cells, interleukin-1β
was also found to increase prostanoid synthesis, increase
Cox-2 mRNA, and decrease Cox-2 mRNA degradation
[73]. Interferon-γ has also been found to stimulate luteal
PGF2α production, but only after 72 h of treatment [74].
Of particular importance, all of the stimulatory effects of
these three cytokines on PGF2α  production could be
inhibited by simultaneous treatment with progesterone
[37,71,74]. Although cytokines increase PGF2α produc-
tion, it does not appear that PGF2α production is required
for cytokine-mediated inhibition of progesterone produc-
tion or induction of cell death because indomethacin
treatment did not prevent these cytokine actions [74,75].
Another peptide that appears to be critical in luteolysis is
endothelin-1 (ET-1; see Milvae [76] for review). Treat-
ment with ET-1 decreases progesterone production from
bovine luteal cells in vitro or in vivo, an effect blocked by a
specific ETA receptor antagonist [77,78]. In bovine micro-
dialized CL, ET-1 was effective at decreasing progesterone
only after CL were exposed to PGF2α [79]. Moreover, there
appears to exist an intraluteal amplification pathway
between PGF2α and ET-1. Treatment with PGF2α induces
ET-1 mRNA and protein in bovine CL [80], and con-
versely treatment with ET-1 will induce PGF2α production
by luteal cells [81]. Thus, ET-1, as well as certain cytokine
peptides, has complex but critical relationships with
PGF2α  and progesterone during luteolysis. Further
research will be required to define the precise temporal
sequence and intracellular mechanisms involved in the
interrelationships of these peptides with the actions and
production of intraluteal PGF2α and progesterone. Estra-
diol-17β, oxytocin, noradrenaline, and nitric oxide have
also been found to stimulate intraluteal PG production
(reviewed in [1]), and these could serve to amplify signals
that reach luteal cells from extraluteal or intraluteal
sources.
Possible Physiological Role of Intraluteal PG 
production
Figure 2 shows a simplified model for the regulation of
PG production in the CL. The LH surge dramatically
induces Cox-2 expression in the granulosa cells, and there
is a subsequent increase in intrafollicular PG production.
This induction is mediated by the cAMP/PKA intracellular
effector system and there is a delay between the LH surge
and Cox-2 expression [82]. The molecular mechanisms
causing this delay in expression are unclear but this allows
PG production to occur only a few hours before the time
of ovulation [83]. This induction of Cox-2 is essential for
ovulation as evidenced by the lack of ovulation in Cox-2
knock-out mice [84]. Binding of PGE2 to the EP2 receptor
appears to be essential for normal ovulation [85].
Within 2 days after the LH surge there is an induction of
FP receptors in the CL [82]. The presence of FP receptor on
the luteinized granulosa cells (large luteal cells) would
allow response to PGF2α. However during this early time
period, treatment with PGF2α does not cause luteolysis. As
reviewed above, the CL of most species produce large
amounts of PGs during the early luteal phase. The physi-
ological importance of intraluteal PG production in the
early CL is not clear. Okuda and Skarzynski [1] suggested
that since luteal production of PGF2α is high in the early
luteal phase of the cow, the early CL may be desensitized
to PGF2α. If so, this would have to be a very specific desen-
sitization, since PGF2α has been shown to stimulate a
number of events in the early CL [63]. Treatment with
indomethacin and sodium meclofenamate during the
early to mid-luteal phase caused a decrease in circulating
progesterone, suggesting a luteotropic role of luteal PGs
[86,87]. However, it is also possible that one of these
inhibitors, meclofenamate, had other direct effects on
luteal cAMP or progesterone production that were inde-
pendent of inhibition of PG production, as suggested by
Zelinski-Wooten et al. [88]. Alternatively, perhaps luteo-
tropic PGs, produced by the CL, protect the CL from lute-
olytic PGF2α during the early luteal phase. In addition, CL
without luteolytic capacity appear to lack the pathways
that induce intraluteal PGF2α production, suggesting that
lack of these pathways is critical to protect the CL from
luteolysis during the early luteal phase. Intraluteal PG
production in the early CL may have numerous other
physiological functions such as blood flow regulation,
intercellular communication, or cellular differentiation
that have not yet been clearly examined.
The physiological role of intraluteal PGF2α production in
the luteolytic cascade has been frequently discussed. In
species without involvement of the uterus in luteal regres-
sion it seems likely that intraluteal production of PGF2α
may be a critical part of the luteolytic mechanism. In pri-
mates, as in other species, changes in the responsivenessReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/91
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of the corpus luteum to PGs as the corpus luteum ages
may be as important as changes in luteal production of
PGs [89,90]. In species with uterine-dependent regression
of the CL, it seems clear that the luteolytic factor secreted
by the uterus is PGF2α. However, the small amounts of
uterine PGF2α could be dramatically amplified by intral-
uteal PGF2α production. As discussed above, this could be
through direct effects of PGF2α on Cox-2 expression and
induction of other PGF2α biosynthesis pathways (Section
III). In addition, PGF2α would decrease luteal progester-
one production and increase luteal cytokine and endothe-
lin production; changes that have all been found to
increase luteal PGF2α production (Section IV). Thus, luteal
PGF2α production could serve to initiate (primates and
possibly other species with uterine-independent luteal
regression) or amplify (species with uterine-dependent
luteal regression) the luteolytic cascade. The intriguing
preliminary report by Griffeth et al. [67] raises the possi-
bility that extraluteal signals (e.g., uterine PGF2α) may ini-
tiate the inhibition of progesterone production that
accompanies luteal regression, but that the increase in
intraluteal PGF2α production may be critical for the struc-
A model for the regulation of PG production during different stages of luteal differentiation Figure 2
A model for the regulation of PG production during different stages of luteal differentiation. In the granulosa cell of the preovu-
latory follicle there is very low PG production and low expression of Cox-2. The LH surge induces Cox-2 expression through 
the protein kinase A (PKA) pathway but with a delay in expression depending upon the species [83]. In the early luteal cell 
there is high PG production that is stimulated by pathways that have not yet been defined. It is also possible that high Cox-2 
protein has been left after the dramatic induction of Cox-2 after the LH surge. In the early luteal cell and in the CL without 
luteolytic capacity (these 2 stages may overlap), there are PGF2α receptors but PGF2α does not stimulate increased intraluteal 
PG production (shown by red lines). In addition, PGF2α does not induce other activators of PG production, such as decreased 
progesterone secretion, increased endothelin-1 production, or increased cytokine production. Unknown mechanisms cause 
the CL to acquire luteolytic capacity. After acquisition of luteolytic capacity, treatment with PGF2α increases intraluteal PG pro-
duction. Activation of cytosolic phospholipase A2 (cPLA2) by increased free intracellular calcium concentrations provides ara-
chidonic acid (A.A.) substrate to the induced Cox-2 enzyme. Although not shown, these events are likely to be localized to the 
nuclear membrane. Intraluteal PGF2α production activates an autoamplification loop in the mature CL due to PGF2α-induced 
Cox-2 expression and PGF2α induction of other activators of Cox-2 expression.
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tural demise of the CL. In addition, intraluteal PGE2 pro-
duction is increased to a similar extent as PGF2α
production during luteolysis [91]. Similarly, we have con-
sistently found intraluteal PGE2 and PGF2α production to
be highly correlated (LA Anderson and MC Wiltbank,
unpublished results). It seems likely that increased pro-
duction of both PGs is mediated by the increased Cox-2
and PLA2 activity associated with luteolysis. A possible
physiological role for increased intraluteal PGE during
luteolysis is not clear; indeed, the PGE increase seems
counterintuitive given the reported luteal protective
effects of PGEs [92]. It seems clear that in spite of the sub-
stantial scientific progress that has been achieved in this
research area in the past few years, there still remain
numerous physiological and molecular questions related
to intraluteal PG production.
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